Algernon Pharmaceuticals Inc (AGNPF)

[shell3]

Outstanding: 166,986,769 for May 11, 2021

Monthly 5th Report

https://webfiles.thecse.com/4_-_Algernon_-_CSE_Form_7_-_April_Monthly_Progress_Report_FINAL_0.pdf?Jf_dPYg3sWWIgGYla7rypjjTdkKXqBLl

The Company is conducting a Phase 2 clinical trial for IPF and chronic cough in Australia and New Zealand. The study achieved 50% enrolment on May 11, 2021.

The Company announced on February 1st, 20201 that it had launched a new clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”). The Company has begun its DMT pre- clinical research program with Charles River Laboratories, a global contract research organization and has begun the early stages of cGMP DMT API manufacturing with Dalton Pharma Services.

The Company completed its primary analysis of all of the full data set from its phase 2b/3 study of Ifenprodil for COVID-19.

On April 26, 2021 the Company filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and Drug Administration (“FDA”), based on the completion of the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil).